CellsBin closes Series A to advance rare-cell analysis platform
108 BioCapital led the financing for tools that detect, profile and track rare cells to help researchers study disease and treatment response.
Making rare cells measurable over time
CellsBin combines microfluidics, multimodal imaging and single-cell analysis to detect and profile rare cells that conventional samples can miss. Its platform adds longitudinal monitoring and AI analysis, giving researchers a way to study how cellular populations change over time and how patients may respond differently to therapy.
The company’s initial applications include cell and gene therapy monitoring and hematologic cancers. Its Scout and Polaris tools are intended to make rare-cell signals visible and actionable for research and clinical development.
Use of funds
Accelerate commercialization and strategic partnerships
Develop products
Expand clinical and technical capabilities